MX2009009916A - Tetrahidroquinolinas sustituidas. - Google Patents

Tetrahidroquinolinas sustituidas.

Info

Publication number
MX2009009916A
MX2009009916A MX2009009916A MX2009009916A MX2009009916A MX 2009009916 A MX2009009916 A MX 2009009916A MX 2009009916 A MX2009009916 A MX 2009009916A MX 2009009916 A MX2009009916 A MX 2009009916A MX 2009009916 A MX2009009916 A MX 2009009916A
Authority
MX
Mexico
Prior art keywords
substituted tetrahydroquinolines
tetrahydroquinolines
substituted
compounds
tumors
Prior art date
Application number
MX2009009916A
Other languages
English (en)
Inventor
Dirk Finsinger
Christiane Amendt
Frank Zenke
Kai Schiemann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2009009916A publication Critical patent/MX2009009916A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de la fórmula I (ver fórmula (I)) en donde R1, R2, R3, R4, R5, X, Y, W, Q1, Q2, Z, s y m tienen los significados indicados en la reivindicación 1, se pueden utilizar, entre otras cosas, para el tratamiento de tumores.
MX2009009916A 2007-03-20 2008-02-21 Tetrahidroquinolinas sustituidas. MX2009009916A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007013855A DE102007013855A1 (de) 2007-03-20 2007-03-20 Substituierte Tetrahydrochinoline
PCT/EP2008/001353 WO2008113451A1 (de) 2007-03-20 2008-02-21 Substituierte tetrahydrochinoline

Publications (1)

Publication Number Publication Date
MX2009009916A true MX2009009916A (es) 2009-10-19

Family

ID=39456401

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009916A MX2009009916A (es) 2007-03-20 2008-02-21 Tetrahidroquinolinas sustituidas.

Country Status (16)

Country Link
US (1) US8524732B2 (es)
EP (1) EP2121700B1 (es)
JP (1) JP5480636B2 (es)
KR (1) KR20090120005A (es)
CN (1) CN101641362A (es)
AR (1) AR065787A1 (es)
AU (1) AU2008228565B2 (es)
BR (1) BRPI0808938A2 (es)
CA (1) CA2681256C (es)
DE (1) DE102007013855A1 (es)
EA (1) EA200901179A1 (es)
ES (1) ES2394535T3 (es)
IL (1) IL200964A (es)
MX (1) MX2009009916A (es)
WO (1) WO2008113451A1 (es)
ZA (1) ZA200907305B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011084439A1 (en) * 2009-12-17 2011-07-14 Sanofi Tetrahydrocarboline derivatives as eg5 inhibitors
US9263716B2 (en) * 2013-02-21 2016-02-16 Lutron Electronics Co., Inc. Monolithic battery holder having resilient retention strap for use in battery-powered sensor
US9498540B2 (en) 2013-03-15 2016-11-22 Novartis Ag Cell proliferation inhibitors and conjugates thereof
TW201636329A (zh) 2015-02-02 2016-10-16 佛瑪治療公司 作為ｈｄａｃ抑制劑之雙環［４，６，０］異羥肟酸
EA201792673A1 (ru) 2015-02-02 2018-04-30 Форма Терапьютикс, Инк. 3-арил-4-амидобициклические [4,5,0] гидроксамовые кислоты в качестве ингибиторов hdac
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5428051A (en) 1992-10-13 1995-06-27 University Of North Carolina Methods of combating pneumocystis carinii pneumonia and compounds useful therefor
DK0657422T3 (da) 1993-12-09 1998-10-12 Ono Pharmaceutical Co Naphthyloxyeddikesyrederivater som PEG2-agonister og -antagonister
US5521189A (en) 1994-05-06 1996-05-28 The University Of Nc At Ch Methods of treating pneumocystis carinii pneumonia
US5602172A (en) 1994-05-06 1997-02-11 The University Of North Carolina At Chapel Hill Methods of inhibiting Pneumocystis carinii pneumonia, Giardia lamblia, and Cryptosporidium and compounds useful therefor
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US5723495A (en) 1995-11-16 1998-03-03 The University Of North Carolina At Chapel Hill Benzamidoxime prodrugs as antipneumocystic agents
ES2198139T3 (es) 1998-08-20 2004-01-16 The University Of North Carolina At Chapel Hill Compuestos de dibenzotiofeno y procedimientos de uso de los mismos.
WO2000015212A2 (en) 1998-09-17 2000-03-23 The University Of North Carolina At Chapel Hill Antifungal activity of dicationic molecules
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODY FOR INCREASING IRRADIATION IN CANCER THERAPY
WO2001003685A2 (en) 1999-07-08 2001-01-18 The University Of North Carolina At Chapel Hill Novel prodrugs for antimicrobial amidines
US6325395B1 (en) 2000-02-07 2001-12-04 Jeffrey L. Frymoyer Wheeled buoyant decoy transporting device
US6569853B1 (en) 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US7250423B2 (en) 2001-09-24 2007-07-31 Chao-Jun Li Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers
PL2033959T3 (pl) 2003-12-20 2011-09-30 Merck Patent Gmbh Pochodne tetrahydropiranochinolinowe
DE102005027170A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Substituierte Tetrahydrochinoline
JP4655821B2 (ja) * 2005-08-23 2011-03-23 株式会社日立製作所 脳機能計測用刺激呈示装置

Also Published As

Publication number Publication date
KR20090120005A (ko) 2009-11-23
EP2121700B1 (de) 2012-10-03
US20100022579A1 (en) 2010-01-28
ZA200907305B (en) 2010-06-30
CN101641362A (zh) 2010-02-03
JP2010521503A (ja) 2010-06-24
IL200964A0 (en) 2010-05-17
IL200964A (en) 2016-10-31
AU2008228565B2 (en) 2012-09-20
JP5480636B2 (ja) 2014-04-23
CA2681256C (en) 2015-06-02
AR065787A1 (es) 2009-07-01
BRPI0808938A2 (pt) 2014-08-19
US8524732B2 (en) 2013-09-03
WO2008113451A1 (de) 2008-09-25
EP2121700A1 (de) 2009-11-25
DE102007013855A1 (de) 2008-09-25
EA200901179A1 (ru) 2010-04-30
ES2394535T3 (es) 2013-02-01
AU2008228565A1 (en) 2008-09-25
CA2681256A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
MX2009012708A (es) Derivados de piridazinona.
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
MX2010003368A (es) Derivados de imidazol.
MY153727A (en) Pyridazinone derivatives
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
MX2009012709A (es) Derivados de arileter-piridazinona.
MX2009008798A (es) Derivados de iminipiridina y sus usos como microbicidas.
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
TW200745004A (en) Novel compounds, their preparation and use
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
PH12012501905A1 (en) Quinoline derivatives and their use as fungicides
MX2009013077A (es) Derivados dde benzoxazolona.
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
TW200630367A (en) Substituted adenines and the uses thereof
TW200700064A (en) Novel compounds
MX2010009576A (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
TW200722424A (en) Substituted piperidines
TW200700358A (en) Organic compounds
MX2011007165A (es) Derivados de piridazinona.
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
IL200469A0 (en) Benzimidazole derivatives
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
IL207639A (en) PyrrollopyrimidineCarboxylate compounds, preparations containing them and their uses
MX2012006696A (es) Derivados de 3, 4, 4a, 10b-tetrahidro-1h-tiopirano-[4, 3-c]-isoqunolina.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal